Acute Leukemia

Observed

← altered in cohorts of

PRSS1

219 / 768 cases (29 %) · ssm · TARGET-ALL-P2

—

Observed

← altered in cohorts of

PRSS2

218 / 768 cases (28 %) · ssm · TARGET-ALL-P2

—

Observed

← altered in cohorts of

CDKN2A

209 / 768 cases (27 %) · ssm · TARGET-ALL-P2

—

Observed

← altered in cohorts of

MTRNR2L6

209 / 768 cases (27 %) · ssm · TARGET-ALL-P2

—

Observed

← altered in cohorts of

NPM1

233 / 903 cases (26 %) · ssm · aml_ohsu_2022 · largest of 7 cohorts

—

Observed

← altered in cohorts of

CDKN2B

183 / 768 cases (24 %) · ssm · TARGET-ALL-P2

—

Observed

← altered in cohorts of

MTAP

170 / 768 cases (22 %) · ssm · TARGET-ALL-P2

—

Observed

← altered in cohorts of

DNMT3A

197 / 903 cases (22 %) · ssm · aml_ohsu_2022 · largest of 5 cohorts

—

Observed

← altered in cohorts of

NOTCH1

163 / 768 cases (21 %) · ssm · TARGET-ALL-P2

—

Observed

← altered in cohorts of

DMRTA1

126 / 768 cases (16 %) · ssm · TARGET-ALL-P2

—

Observed

← altered in cohorts of

VIPR2

29 / 200 cases (14 %) · ssm · TCGA-LAML

—

Observed

← altered in cohorts of

IFNE

111 / 768 cases (14 %) · ssm · TARGET-ALL-P2

—

Observed

← altered in cohorts of

IFNA1

108 / 768 cases (14 %) · ssm · TARGET-ALL-P2

—

Observed

← altered in cohorts of

IFNA8

108 / 768 cases (14 %) · ssm · TARGET-ALL-P2

—

Observed

← altered in cohorts of

IFNA2

106 / 768 cases (14 %) · ssm · TARGET-ALL-P2

—

Observed

← altered in cohorts of

IFNA6

106 / 768 cases (14 %) · ssm · TARGET-ALL-P2

—

Observed

← altered in cohorts of

IFNA13

105 / 768 cases (14 %) · ssm · TARGET-ALL-P2

—

Observed

← altered in cohorts of

C8orf33

27 / 200 cases (14 %) · ssm · TCGA-LAML

—

Observed

← altered in cohorts of

COMMD5

27 / 200 cases (14 %) · ssm · TCGA-LAML

—

Observed

← altered in cohorts of

DLGAP2

27 / 200 cases (14 %) · ssm · TCGA-LAML

—

Observed

← altered in cohorts of

MYC

27 / 200 cases (14 %) · ssm · TCGA-LAML

—

Observed

← altered in cohorts of

RPL8

27 / 200 cases (14 %) · ssm · TCGA-LAML

—

Observed

← altered in cohorts of

ZNF16

27 / 200 cases (14 %) · ssm · TCGA-LAML

—

Observed

← altered in cohorts of

ZNF250

27 / 200 cases (14 %) · ssm · TCGA-LAML

—

Observed

← altered in cohorts of

ZNF517

27 / 200 cases (14 %) · ssm · TCGA-LAML

—

Observed

← altered in cohorts of

ZNF7

27 / 200 cases (14 %) · ssm · TCGA-LAML

—

Observed

← altered in cohorts of

IFNA5

103 / 768 cases (13 %) · ssm · TARGET-ALL-P2

—

Observed

← altered in cohorts of

KLHL9

103 / 768 cases (13 %) · ssm · TARGET-ALL-P2

—

Observed

← altered in cohorts of

NRAS

119 / 903 cases (13 %) · ssm · aml_ohsu_2022 · largest of 6 cohorts

—

Observed

← altered in cohorts of

TET2

118 / 903 cases (13 %) · ssm · aml_ohsu_2022 · largest of 2 cohorts

—

Observed

← altered in cohorts of

COL22A1

26 / 200 cases (13 %) · ssm · TCGA-LAML

—

Observed

← altered in cohorts of

CYC1

26 / 200 cases (13 %) · ssm · TCGA-LAML

—

Observed

← altered in cohorts of

DYNC2I1

26 / 200 cases (13 %) · ssm · TCGA-LAML

—

Observed

← altered in cohorts of

ERICH1

26 / 200 cases (13 %) · ssm · TCGA-LAML

—

Observed

← altered in cohorts of

FBXO25

26 / 200 cases (13 %) · ssm · TCGA-LAML

—

Observed

← altered in cohorts of

LY6D

26 / 200 cases (13 %) · ssm · TCGA-LAML

—

Observed

← altered in cohorts of

LY6K

26 / 200 cases (13 %) · ssm · TCGA-LAML

—

Observed

← altered in cohorts of

LYNX1

26 / 200 cases (13 %) · ssm · TCGA-LAML

—

Observed

← altered in cohorts of

LYNX1-SLURP2

26 / 200 cases (13 %) · ssm · TCGA-LAML

—

Observed

← altered in cohorts of

LYPD2

26 / 200 cases (13 %) · ssm · TCGA-LAML

—

Observed

← altered in cohorts of

OR4F21

26 / 200 cases (13 %) · ssm · TCGA-LAML

—

Observed

← altered in cohorts of

PSCA

26 / 200 cases (13 %) · ssm · TCGA-LAML

—

Observed

← altered in cohorts of

PUF60

26 / 200 cases (13 %) · ssm · TCGA-LAML

—

Observed

← altered in cohorts of

SLURP1

26 / 200 cases (13 %) · ssm · TCGA-LAML

—

Observed

← altered in cohorts of

SLURP2

26 / 200 cases (13 %) · ssm · TCGA-LAML

—

Observed

← altered in cohorts of

TDRP

26 / 200 cases (13 %) · ssm · TCGA-LAML

—

Observed

← altered in cohorts of

26 / 200 cases (13 %) · ssm · TCGA-LAML

—

Observed

← altered in cohorts of

THEM6

26 / 200 cases (13 %) · ssm · TCGA-LAML

—

Observed

← altered in cohorts of

TRPV5

26 / 200 cases (13 %) · ssm · TCGA-LAML

—

Observed

← altered in cohorts of

ZNF34

26 / 200 cases (13 %) · ssm · TCGA-LAML

—

Observed

← altered in cohorts of

ZNF596

26 / 200 cases (13 %) · ssm · TCGA-LAML

—

Observed

← altered in cohorts of

ZNF783

26 / 200 cases (13 %) · ssm · TCGA-LAML

—

Observed

← altered in cohorts of

IFNA16

99 / 768 cases (13 %) · ssm · TARGET-ALL-P2

—

Observed

← altered in cohorts of

IFNA17

99 / 768 cases (13 %) · ssm · TARGET-ALL-P2

—

Observed

← altered in cohorts of

IFNA10

98 / 768 cases (13 %) · ssm · TARGET-ALL-P2

—

Observed

← altered in cohorts of

IFNA14

98 / 768 cases (13 %) · ssm · TARGET-ALL-P2

—

Observed

← altered in cohorts of

IFNA7

98 / 768 cases (13 %) · ssm · TARGET-ALL-P2

—

Observed

← altered in cohorts of

ABCF2

25 / 200 cases (13 %) · ssm · TCGA-LAML

—

Observed

← altered in cohorts of

ADCY8

25 / 200 cases (13 %) · ssm · TCGA-LAML

—

Observed

← altered in cohorts of

ADGRB1

25 / 200 cases (13 %) · ssm · TCGA-LAML

—

Observed

← altered in cohorts of

AGO2

25 / 200 cases (13 %) · ssm · TCGA-LAML

—

Observed

← altered in cohorts of

ARC

25 / 200 cases (13 %) · ssm · TCGA-LAML

—

Observed

← altered in cohorts of

ARHGAP39

25 / 200 cases (13 %) · ssm · TCGA-LAML

—

Observed

← altered in cohorts of

ARMC1

25 / 200 cases (13 %) · ssm · TCGA-LAML

—

Observed

← altered in cohorts of

ASAP1

25 / 200 cases (13 %) · ssm · TCGA-LAML

—

Observed

← altered in cohorts of

BOP1

25 / 200 cases (13 %) · ssm · TCGA-LAML

—

Observed

← altered in cohorts of

CCN4

25 / 200 cases (13 %) · ssm · TCGA-LAML

—

Observed

← altered in cohorts of

CSMD3

25 / 200 cases (13 %) · ssm · TCGA-LAML

—

Observed

← altered in cohorts of

CYP11B1

25 / 200 cases (13 %) · ssm · TCGA-LAML

—

Observed

← altered in cohorts of

CYP11B2

25 / 200 cases (13 %) · ssm · TCGA-LAML

—

Observed

← altered in cohorts of

EEF1D

25 / 200 cases (13 %) · ssm · TCGA-LAML

—

Observed

← altered in cohorts of

EFR3A

25 / 200 cases (13 %) · ssm · TCGA-LAML

—

Observed

← altered in cohorts of

EPPK1

25 / 200 cases (13 %) · ssm · TCGA-LAML

—

Observed

← altered in cohorts of

ESYT2

25 / 200 cases (13 %) · ssm · TCGA-LAML

—

Observed

← altered in cohorts of

EXOSC4

25 / 200 cases (13 %) · ssm · TCGA-LAML

—

Observed

← altered in cohorts of

GALNTL5

25 / 200 cases (13 %) · ssm · TCGA-LAML

—

Observed

← altered in cohorts of

GBX1

25 / 200 cases (13 %) · ssm · TCGA-LAML

—

Observed

← altered in cohorts of

GIMAP8

25 / 200 cases (13 %) · ssm · TCGA-LAML

—

Observed

← altered in cohorts of

GLI4

25 / 200 cases (13 %) · ssm · TCGA-LAML

—

Observed

← altered in cohorts of

GML

25 / 200 cases (13 %) · ssm · TCGA-LAML

—

Observed

← altered in cohorts of

GPAA1

25 / 200 cases (13 %) · ssm · TCGA-LAML

—

Observed

← altered in cohorts of

GPR20

25 / 200 cases (13 %) · ssm · TCGA-LAML

—

Observed

← altered in cohorts of

GRINA

25 / 200 cases (13 %) · ssm · TCGA-LAML

—

Observed

← altered in cohorts of

GSDMC

25 / 200 cases (13 %) · ssm · TCGA-LAML

—

Observed

← altered in cohorts of

HHLA1

25 / 200 cases (13 %) · ssm · TCGA-LAML

—

Observed

← altered in cohorts of

HSF1

25 / 200 cases (13 %) · ssm · TCGA-LAML

—

Observed

← altered in cohorts of

HTR5A

25 / 200 cases (13 %) · ssm · TCGA-LAML

—

Observed

← altered in cohorts of

IFNA4

96 / 768 cases (13 %) · ssm · TARGET-ALL-P2

—

Observed

← altered in cohorts of

JRK

25 / 200 cases (13 %) · ssm · TCGA-LAML

—

Observed

← altered in cohorts of

KCNH2

25 / 200 cases (13 %) · ssm · TCGA-LAML

—

Observed

← altered in cohorts of

KCNK9

25 / 200 cases (13 %) · ssm · TCGA-LAML

—

Observed

← altered in cohorts of

KCNQ3

25 / 200 cases (13 %) · ssm · TCGA-LAML

—

Observed

← altered in cohorts of

KHDRBS3

25 / 200 cases (13 %) · ssm · TCGA-LAML

—

Observed

← altered in cohorts of

LRRC14

25 / 200 cases (13 %) · ssm · TCGA-LAML

—

Observed

← altered in cohorts of

LY6E

25 / 200 cases (13 %) · ssm · TCGA-LAML

—

Observed

← altered in cohorts of

LY6H

25 / 200 cases (13 %) · ssm · TCGA-LAML

—

Observed

← altered in cohorts of

MAF1

25 / 200 cases (13 %) · ssm · TCGA-LAML

—

Observed

← altered in cohorts of

MFSD3

25 / 200 cases (13 %) · ssm · TCGA-LAML

—

Observed

← altered in cohorts of

MROH1

25 / 200 cases (13 %) · ssm · TCGA-LAML

—

Observed

← altered in cohorts of

MROH6

25 / 200 cases (13 %) · ssm · TCGA-LAML

—

Observed

← altered in cohorts of

NAPRT

25 / 200 cases (13 %) · ssm · TCGA-LAML

—

Observed

← altered in cohorts of

NDRG1

25 / 200 cases (13 %) · ssm · TCGA-LAML

—

Observed

← altered in cohorts of

NRBP2

25 / 200 cases (13 %) · ssm · TCGA-LAML

—

Observed

← altered in cohorts of

NSMCE2

25 / 200 cases (13 %) · ssm · TCGA-LAML

—

Observed

← altered in cohorts of

OPRK1

25 / 200 cases (13 %) · ssm · TCGA-LAML

—

Observed

← altered in cohorts of

PHF20L1

25 / 200 cases (13 %) · ssm · TCGA-LAML

—

Observed

← altered in cohorts of

POU5F1B

25 / 200 cases (13 %) · ssm · TCGA-LAML

—

Observed

← altered in cohorts of

PPP1R16A

25 / 200 cases (13 %) · ssm · TCGA-LAML

—

Observed

← altered in cohorts of

PTP4A3

25 / 200 cases (13 %) · ssm · TCGA-LAML

—

Observed

← altered in cohorts of

PYCR3

25 / 200 cases (13 %) · ssm · TCGA-LAML

—

Observed

← altered in cohorts of

REPIN1

25 / 200 cases (13 %) · ssm · TCGA-LAML

—

Observed

← altered in cohorts of

RHPN1

25 / 200 cases (13 %) · ssm · TCGA-LAML

—

Observed

← altered in cohorts of

SCRIB

25 / 200 cases (13 %) · ssm · TCGA-LAML

—

Observed

← altered in cohorts of

SHARPIN

25 / 200 cases (13 %) · ssm · TCGA-LAML

—

Observed

← altered in cohorts of

SLC45A4

25 / 200 cases (13 %) · ssm · TCGA-LAML

—

Observed

← altered in cohorts of

TRAPPC9

25 / 200 cases (13 %) · ssm · TCGA-LAML

—

Observed

← altered in cohorts of

TRIB1

25 / 200 cases (13 %) · ssm · TCGA-LAML

—

Observed

← altered in cohorts of

XKR4

25 / 200 cases (13 %) · ssm · TCGA-LAML

—

Observed

← altered in cohorts of

ZBED6CL

25 / 200 cases (13 %) · ssm · TCGA-LAML

—

Observed

← altered in cohorts of

ZFAT

25 / 200 cases (13 %) · ssm · TCGA-LAML

—

Observed

← altered in cohorts of

ZFHX4

25 / 200 cases (13 %) · ssm · TCGA-LAML

—

Observed

← altered in cohorts of

ZNF251

25 / 200 cases (13 %) · ssm · TCGA-LAML

—

Observed

← altered in cohorts of

ZNF623

25 / 200 cases (13 %) · ssm · TCGA-LAML

—

Observed

← altered in cohorts of

ZNF746

25 / 200 cases (13 %) · ssm · TCGA-LAML

—

Observed

← altered in cohorts of

IFNA21

95 / 768 cases (12 %) · ssm · TARGET-ALL-P2

—

Observed

← altered in cohorts of

IDH2

111 / 903 cases (12 %) · ssm · aml_ohsu_2022 · largest of 5 cohorts

—

Observed

← altered in cohorts of

IFNW1

93 / 768 cases (12 %) · ssm · TARGET-ALL-P2

—

Observed

← altered in cohorts of

SRSF2

109 / 903 cases (12 %) · ssm · aml_ohsu_2022 · largest of 2 cohorts

—

Observed

← altered in cohorts of

RUNX1

108 / 903 cases (12 %) · ssm · aml_ohsu_2022 · largest of 2 cohorts

—

Observed

← altered in cohorts of

IFNB1

90 / 768 cases (12 %) · ssm · TARGET-ALL-P2

—

Observed

← altered in cohorts of

HACD4

86 / 768 cases (11 %) · ssm · TARGET-ALL-P2

—

Observed

← altered in cohorts of

ASXL1

93 / 903 cases (10 %) · ssm · aml_ohsu_2022 · largest of 2 cohorts

—

Observed

← altered in cohorts of

ELAVL2

77 / 768 cases (10 %) · ssm · TARGET-ALL-P2

—

Observed

← altered in cohorts of

KIT

88 / 887 cases (9.9 %) · ssm · aml_stjude_2024 · largest of 2 cohorts

—

Observed

← altered in cohorts of

FOCAD

76 / 768 cases (9.9 %) · ssm · TARGET-ALL-P2

—

Observed

← altered in cohorts of

PAX5

74 / 768 cases (9.6 %) · ssm · TARGET-ALL-P2

—

Observed

← altered in cohorts of

FBXW7

71 / 768 cases (9.2 %) · ssm · TARGET-ALL-P2

—

Observed

← altered in cohorts of

TP53

82 / 903 cases (9.1 %) · ssm · aml_ohsu_2022 · largest of 2 cohorts

—

Observed

← altered in cohorts of

IZUMO3

69 / 768 cases (9.0 %) · ssm · TARGET-ALL-P2

—

Observed

← altered in cohorts of

KRAS

78 / 887 cases (8.8 %) · ssm · aml_stjude_2024 · largest of 3 cohorts

—

Observed

← altered in cohorts of

JAK2

66 / 768 cases (8.6 %) · ssm · TARGET-ALL-P2

—

Observed

← altered in cohorts of

MLLT3

63 / 768 cases (8.2 %) · ssm · TARGET-ALL-P2

—

Observed

← altered in cohorts of

TUSC1

62 / 768 cases (8.1 %) · ssm · TARGET-ALL-P2

—

Observed

← altered in cohorts of

WT1

72 / 903 cases (8.0 %) · ssm · aml_ohsu_2022 · largest of 5 cohorts

—

Observed

← altered in cohorts of

IDH1

71 / 903 cases (7.9 %) · ssm · aml_ohsu_2022 · largest of 2 cohorts

—

Observed

← altered in cohorts of

EQTN

60 / 768 cases (7.8 %) · ssm · TARGET-ALL-P2

—

Observed

← altered in cohorts of

OR4Q3

59 / 768 cases (7.7 %) · ssm · TARGET-ALL-P2

—

Observed

← altered in cohorts of

MDN1

58 / 768 cases (7.6 %) · ssm · TARGET-ALL-P2

—

Observed

← altered in cohorts of

OR4M1

58 / 768 cases (7.6 %) · ssm · TARGET-ALL-P2

—

Observed

← altered in cohorts of

POTEG

58 / 768 cases (7.6 %) · ssm · TARGET-ALL-P2

—

Observed

← altered in cohorts of

TEK

58 / 768 cases (7.6 %) · ssm · TARGET-ALL-P2

—

Observed

← altered in cohorts of

OR11H12

57 / 768 cases (7.4 %) · ssm · TARGET-ALL-P2

—

Observed

← altered in cohorts of

OR11H2

57 / 768 cases (7.4 %) · ssm · TARGET-ALL-P2

—

Observed

← altered in cohorts of

OR4N2

57 / 768 cases (7.4 %) · ssm · TARGET-ALL-P2

—

Observed

← altered in cohorts of

PLAA

57 / 768 cases (7.4 %) · ssm · TARGET-ALL-P2

—

Observed

← altered in cohorts of

POTEM

57 / 768 cases (7.4 %) · ssm · TARGET-ALL-P2

—

Observed

← altered in cohorts of

PTEN

57 / 768 cases (7.4 %) · ssm · TARGET-ALL-P2

—

Observed

← altered in cohorts of

C9orf72

56 / 768 cases (7.3 %) · ssm · TARGET-ALL-P2

—

Observed

← altered in cohorts of

CAAP1

56 / 768 cases (7.3 %) · ssm · TARGET-ALL-P2

—

Observed

← altered in cohorts of

IFT74

56 / 768 cases (7.3 %) · ssm · TARGET-ALL-P2

—

Observed

← altered in cohorts of

LRRC19

56 / 768 cases (7.3 %) · ssm · TARGET-ALL-P2

—

Observed

← altered in cohorts of

OR4K2

56 / 768 cases (7.3 %) · ssm · TARGET-ALL-P2

—

Observed

← altered in cohorts of

OR4K5

56 / 768 cases (7.3 %) · ssm · TARGET-ALL-P2

—

Observed

← altered in cohorts of

ZNF292

56 / 768 cases (7.3 %) · ssm · TARGET-ALL-P2

—

Observed

← altered in cohorts of

BACH2

55 / 768 cases (7.2 %) · ssm · TARGET-ALL-P2

—

Observed

← altered in cohorts of

CASP8AP2

55 / 768 cases (7.2 %) · ssm · TARGET-ALL-P2

—

Observed

← altered in cohorts of

EPHA7

55 / 768 cases (7.2 %) · ssm · TARGET-ALL-P2

—

Observed

← altered in cohorts of

GABRR2

55 / 768 cases (7.2 %) · ssm · TARGET-ALL-P2

—

Observed

← altered in cohorts of

GRIK2

55 / 768 cases (7.2 %) · ssm · TARGET-ALL-P2

—

Observed

← altered in cohorts of

IFNK

55 / 768 cases (7.2 %) · ssm · TARGET-ALL-P2

—

Observed

← altered in cohorts of

LINGO2

55 / 768 cases (7.2 %) · ssm · TARGET-ALL-P2

—

Observed

← altered in cohorts of

MOB3B

55 / 768 cases (7.2 %) · ssm · TARGET-ALL-P2

—

Observed

← altered in cohorts of

OR4K1

55 / 768 cases (7.2 %) · ssm · TARGET-ALL-P2

—

Observed

← altered in cohorts of

ANKRD6

54 / 768 cases (7.0 %) · ssm · TARGET-ALL-P2

—

Observed

← altered in cohorts of

CFAP206

54 / 768 cases (7.0 %) · ssm · TARGET-ALL-P2

—

Observed

← altered in cohorts of

CGA

54 / 768 cases (7.0 %) · ssm · TARGET-ALL-P2

—

Observed

← altered in cohorts of

DOP1A

54 / 768 cases (7.0 %) · ssm · TARGET-ALL-P2

—

Observed

← altered in cohorts of

GABRR1

54 / 768 cases (7.0 %) · ssm · TARGET-ALL-P2

—

Observed

← altered in cohorts of

GJA10

54 / 768 cases (7.0 %) · ssm · TARGET-ALL-P2

—

Observed

← altered in cohorts of

LYRM2

54 / 768 cases (7.0 %) · ssm · TARGET-ALL-P2

—

Observed

← altered in cohorts of

MAP3K7

54 / 768 cases (7.0 %) · ssm · TARGET-ALL-P2

—

Observed

← altered in cohorts of

RRAGD

54 / 768 cases (7.0 %) · ssm · TARGET-ALL-P2

—

Observed

← altered in cohorts of

SNAP91

54 / 768 cases (7.0 %) · ssm · TARGET-ALL-P2

—

Observed

← altered in cohorts of

SNX14

54 / 768 cases (7.0 %) · ssm · TARGET-ALL-P2

—

Observed

← altered in cohorts of

TTN

54 / 768 cases (7.0 %) · ssm · TARGET-ALL-P2

—

Observed

← altered in cohorts of

UBE2J1

54 / 768 cases (7.0 %) · ssm · TARGET-ALL-P2

—

Observed

← altered in cohorts of

CNR1

53 / 768 cases (6.9 %) · ssm · TARGET-ALL-P2

—

Observed

← altered in cohorts of

GRHPR

53 / 768 cases (6.9 %) · ssm · TARGET-ALL-P2

—

Observed

← altered in cohorts of

MPDZ

53 / 768 cases (6.9 %) · ssm · TARGET-ALL-P2

—

Observed

← altered in cohorts of

MRAP2

53 / 768 cases (6.9 %) · ssm · TARGET-ALL-P2

—

Observed

← altered in cohorts of

PM20D2

53 / 768 cases (6.9 %) · ssm · TARGET-ALL-P2

—

Observed

← altered in cohorts of

PNRC1

53 / 768 cases (6.9 %) · ssm · TARGET-ALL-P2

—

Observed

← altered in cohorts of

PRSS35

53 / 768 cases (6.9 %) · ssm · TARGET-ALL-P2

—

Observed

← altered in cohorts of

RNGTT

53 / 768 cases (6.9 %) · ssm · TARGET-ALL-P2

—

Observed

← altered in cohorts of

SRSF12

53 / 768 cases (6.9 %) · ssm · TARGET-ALL-P2

—

Observed

← altered in cohorts of

CYB5R4

52 / 768 cases (6.8 %) · ssm · TARGET-ALL-P2

—

Observed

← altered in cohorts of

FUT9

52 / 768 cases (6.8 %) · ssm · TARGET-ALL-P2

—

Observed

← altered in cohorts of

HTR1E

52 / 768 cases (6.8 %) · ssm · TARGET-ALL-P2

—

Observed

← altered in cohorts of

KLHL32

52 / 768 cases (6.8 %) · ssm · TARGET-ALL-P2

—

Observed

Acute Leukemia investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 243show all (up to 200)
→ investigated in trials for	Cytarabinesmall molecule 522 trials (142 active) · roll-up of the cancer and its descendants	—	—	Acute Leukemia	522	Observed	clinicaltrials	graph →
→ investigated in trials for	Cyclophosphamidesmall molecule 370 trials (142 active) · roll-up of the cancer and its descendants	—	—	Acute Leukemia	370	Observed	clinicaltrials	graph →
→ investigated in trials for	Fludarabinesmall molecule 361 trials (126 active) · roll-up of the cancer and its descendants	—	—	Acute Leukemia	361	Observed	clinicaltrials	graph →
→ investigated in trials for	Venetoclaxsmall molecule 308 trials (200 active) · roll-up of the cancer and its descendants	—	—	Acute Leukemia	308	Observed	clinicaltrials	graph →
→ investigated in trials for	Azacitidinesmall molecule 295 trials (137 active) · roll-up of the cancer and its descendants	—	—	Acute Leukemia	295	Observed	clinicaltrials	graph →
→ investigated in trials for	Methotrexatesmall molecule 202 trials (65 active) · roll-up of the cancer and its descendants	—	—	Acute Leukemia	202	Observed	clinicaltrials	graph →
→ investigated in trials for	Daunorubicinsmall molecule 155 trials (55 active) · roll-up of the cancer and its descendants	—	—	Acute Leukemia	155	Observed	clinicaltrials	graph →
→ investigated in trials for	Dexamethasonesmall molecule 154 trials (59 active) · roll-up of the cancer and its descendants	—	—	Acute Leukemia	154	Observed	clinicaltrials	graph →
→ investigated in trials for	Vincristinesmall molecule 152 trials (50 active) · roll-up of the cancer and its descendants	—	—	Acute Leukemia	152	Observed	clinicaltrials	graph →
→ investigated in trials for	Decitabinesmall molecule 147 trials (41 active) · roll-up of the cancer and its descendants	—	—	Acute Leukemia	147	Observed	clinicaltrials	graph →
→ investigated in trials for	Etoposidesmall molecule 129 trials (24 active) · roll-up of the cancer and its descendants	—	—	Acute Leukemia	129	Observed	clinicaltrials	graph →
→ investigated in trials for	Idarubicinsmall molecule 116 trials (31 active) · roll-up of the cancer and its descendants	—	—	Acute Leukemia	116	Observed	clinicaltrials	graph →
→ investigated in trials for	Busulfansmall molecule 109 trials (34 active) · roll-up of the cancer and its descendants	—	—	Acute Leukemia	109	Observed	clinicaltrials	graph →
→ investigated in trials for	Mercaptopurinesmall molecule 102 trials (38 active) · roll-up of the cancer and its descendants	—	—	Acute Leukemia	102	Observed	clinicaltrials	graph →
→ investigated in trials for	Blinatumomabmonoclonal antibody 97 trials (65 active) · roll-up of the cancer and its descendants	—	—	Acute Leukemia	97	Observed	clinicaltrials	graph →

Acute Leukemia investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 243show all (up to 200)

→ investigated in trials for

Cytarabinesmall molecule

522 trials (142 active) · roll-up of the cancer and its descendants

—

522

Observed

→ investigated in trials for

Cyclophosphamidesmall molecule

370 trials (142 active) · roll-up of the cancer and its descendants

—

370

Observed

→ investigated in trials for

Fludarabinesmall molecule

361 trials (126 active) · roll-up of the cancer and its descendants

—

361

Observed

→ investigated in trials for

Venetoclaxsmall molecule

308 trials (200 active) · roll-up of the cancer and its descendants

—

308

Observed

→ investigated in trials for

Azacitidinesmall molecule

295 trials (137 active) · roll-up of the cancer and its descendants

—

295

Observed

→ investigated in trials for

Methotrexatesmall molecule

202 trials (65 active) · roll-up of the cancer and its descendants

—

202

Observed

→ investigated in trials for

Daunorubicinsmall molecule

155 trials (55 active) · roll-up of the cancer and its descendants

—

155

Observed

→ investigated in trials for

Dexamethasonesmall molecule

154 trials (59 active) · roll-up of the cancer and its descendants

—

154

Observed

→ investigated in trials for

Vincristinesmall molecule

152 trials (50 active) · roll-up of the cancer and its descendants

—

152

Observed

→ investigated in trials for

Decitabinesmall molecule

147 trials (41 active) · roll-up of the cancer and its descendants

—

147

Observed

→ investigated in trials for

Etoposidesmall molecule

129 trials (24 active) · roll-up of the cancer and its descendants

—

129

Observed

→ investigated in trials for

Idarubicinsmall molecule

116 trials (31 active) · roll-up of the cancer and its descendants

—

116

Observed

→ investigated in trials for

Busulfansmall molecule

109 trials (34 active) · roll-up of the cancer and its descendants

—

109

Observed

→ investigated in trials for

Mercaptopurinesmall molecule

102 trials (38 active) · roll-up of the cancer and its descendants

—

102

Observed

→ investigated in trials for

Blinatumomabmonoclonal antibody

97 trials (65 active) · roll-up of the cancer and its descendants

—

Observed

Acute Leukemia studied in …STUDIED_INderived10 of 4,653show all (up to 200)
→ studied in	NCT03059485Phase 2 · active not recruiting DC/AML Fusion Cell Vaccine vs Observation in Patients Who Achieve a Chemotherapy-induced Remission · condition mapped ALIAS · 4,653 trials mapped (1,455 active)	—	—	Acute Myeloid Leukemia	1	Observed	clinicaltrials	graph →
→ studied in	NCT03187288Phase 1 · completed Study of CFI-400945 Fumarate in Patients With Relapsed or Refractory AML or MDS · condition mapped CURATED_BROADER · 4,653 trials mapped (1,455 active)	—	—	Acute Myeloid Leukemia	1	Observed	clinicaltrials	graph →
→ studied in	NCT03597321Phase 2 · active not recruiting Early Prophylactic Donor Lymphocyte Infusion After Allo-HSCT for Patients With AML · condition mapped CURATED_BROADER · 4,653 trials mapped (1,455 active)	—	—	Acute Myeloid Leukemia	1	Observed	clinicaltrials	graph →
→ studied in	NCT03679650Phase 1 · active not recruiting Dendritic Cell/AML Fusion Cell Vaccine Following Allogeneic Transplantation in AML Patients · condition mapped ALIAS · 4,653 trials mapped (1,455 active)	—	—	Acute Myeloid Leukemia	1	Observed	clinicaltrials	graph →
→ studied in	NCT03739814Phase 2 · recruiting Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia · condition mapped ONTOLOGY_EXACT · 4,653 trials mapped (1,455 active)	—	—	B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative	1	Observed	clinicaltrials	graph →
→ studied in	NCT03802695Phase 1 · recruiting A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies · condition mapped CURATED_BROADER · 4,653 trials mapped (1,455 active)	—	—	Acute Myeloid Leukemia	1	Observed	clinicaltrials	graph →
→ studied in	NCT05424562terminated A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy Receiving Oral Venetoclax Tablets in Canada · condition mapped CURATED_BROADER · 4,653 trials mapped (1,455 active)	—	—	Acute Myeloid Leukemia	1	Observed	clinicaltrials	graph →
→ studied in	NCT05621291NA · recruiting A Multicenter Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-Cell Recovery to Guide Management Following Chimeric Antigen Receptor T-cell (CART) Induced Remission in Children and Young Adults With B Lineage Acute Lymph... · condition mapped CURATED_BROADER · 4,653 trials mapped (1,455 active)	—	—	B Acute Lymphoblastic Leukemia	1	Observed	clinicaltrials	graph →
→ studied in	NCT06738368Phase 2 · suspended Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia · condition mapped ONTOLOGY_EXACT · 4,653 trials mapped (1,455 active)	—	—	B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative	1	Observed	clinicaltrials	graph →
→ studied in	NCT06763341Phase 1 · recruiting A Phase 1 Study of AOH1996 in Patients With Relapsed/Refractory Acute Myeloid Leukemia · condition mapped CURATED_BROADER · 4,653 trials mapped (1,455 active)	—	—	Acute Myeloid Leukemia	1	Observed	clinicaltrials	graph →

Acute Leukemia studied in …STUDIED_INderived10 of 4,653show all (up to 200)

→ studied in

NCT03059485Phase 2 · active not recruiting

DC/AML Fusion Cell Vaccine vs Observation in Patients Who Achieve a Chemotherapy-induced Remission · condition mapped ALIAS · 4,653 trials mapped (1,455 active)

—

Observed

→ studied in

NCT03187288Phase 1 · completed

Study of CFI-400945 Fumarate in Patients With Relapsed or Refractory AML or MDS · condition mapped CURATED_BROADER · 4,653 trials mapped (1,455 active)

—

Observed

→ studied in

NCT03597321Phase 2 · active not recruiting

Early Prophylactic Donor Lymphocyte Infusion After Allo-HSCT for Patients With AML · condition mapped CURATED_BROADER · 4,653 trials mapped (1,455 active)

—

Observed

→ studied in

NCT03679650Phase 1 · active not recruiting

Dendritic Cell/AML Fusion Cell Vaccine Following Allogeneic Transplantation in AML Patients · condition mapped ALIAS · 4,653 trials mapped (1,455 active)

—

Observed

B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative

→ studied in

NCT03739814Phase 2 · recruiting

Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia · condition mapped ONTOLOGY_EXACT · 4,653 trials mapped (1,455 active)

—

Observed

→ studied in

NCT03802695Phase 1 · recruiting

A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies · condition mapped CURATED_BROADER · 4,653 trials mapped (1,455 active)

—

Observed

→ studied in

NCT05424562terminated

A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy Receiving Oral Venetoclax Tablets in Canada · condition mapped CURATED_BROADER · 4,653 trials mapped (1,455 active)

—

Observed

B Acute Lymphoblastic Leukemia

→ studied in

NCT05621291NA · recruiting

A Multicenter Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-Cell Recovery to Guide Management Following Chimeric Antigen Receptor T-cell (CART) Induced Remission in Children and Young Adults With B Lineage Acute Lymph... · condition mapped CURATED_BROADER · 4,653 trials mapped (1,455 active)

—

Observed

B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative

→ studied in

NCT06738368Phase 2 · suspended

Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia · condition mapped ONTOLOGY_EXACT · 4,653 trials mapped (1,455 active)

—

Observed

→ studied in

NCT06763341Phase 1 · recruiting

A Phase 1 Study of AOH1996 in Patients With Relapsed/Refractory Acute Myeloid Leukemia · condition mapped CURATED_BROADER · 4,653 trials mapped (1,455 active)

—

Observed